Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431
Hepion Pharmaceuticals, Inc. (HEPA)
Last hepion pharmaceuticals, inc. earnings: 11/14 05:17 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
EDISON, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that it has dosed the first patient in a 28-day multiple ascending dose clinical trial of CRV431. Designed to assess safety, tolerability and pharmacokinetics of CRV431, this study is the third and final stage of CRV431's streamlined early clinical program, which was agreed upon with the U.S. Food and Drug Administration (“FDA”). Patients in four cohorts will be administered CRV431 in doses ranging from 75 mg to 375 mg in combination with 300 mg tenofovir disoproxil fumarate (TDF) antiviral therapy, over a 28-day period. Each cohort is comprised of four patients, equally divided between hepatitis B e-antigen (“HBeAg”) positive and negative. “Having established safety and tolerability
Show less
Read more
Impact Snapshot
Event Time:
HEPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HEPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HEPA alerts
High impacting Hepion Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
HEPA
News
- Model Medicines Appoints Dr. Launa Aspeslet as Senior Scientific & Clinical Advisor [Yahoo! Finance]Yahoo! Finance
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial [Yahoo! Finance]Yahoo! Finance
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialGlobeNewswire
- Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell [Yahoo! Finance]Yahoo! Finance
- Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellGlobeNewswire
HEPA
Earnings
- 11/20/23 - Miss
HEPA
Sec Filings
- 4/16/24 - Form 10-K
- 4/1/24 - Form NT
- 3/7/24 - Form 4
- HEPA's page on the SEC website